Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice

被引:0
作者
Michael P Kim
Douglas B Evans
Huamin Wang
James L Abbruzzese
Jason B Fleming
Gary E Gallick
机构
[1] The University of Texas M.D. Anderson Cancer Center,Department of Surgical Oncology
[2] The University of Texas M.D. Anderson Cancer Center,Department of Cancer Biology
[3] The University of Texas M.D. Anderson Cancer Center,Department of Pathology
[4] The University of Texas M.D. Anderson Cancer Center,Department of Gastrointestinal Medical Oncology
[5] The University of Texas M.D. Anderson Cancer Center,Department of Genitourinary Medical Oncology
来源
Nature Protocols | 2009年 / 4卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
For decades, xenografts using well-established human tumor cell lines have been the most commonly used models to study human cancers in mice. More recently, human tumors implanted directly into immunodeficient mice have become increasingly popular as evidence accrues that they more accurately recapitulate features of patient tumors. Here we describe our protocols for the orthotopic and heterotopic implantation of pancreatic cancer cell lines and freshly isolated patient tumors into immunodeficient mice. We also describe procedures for the digestion of tumors into single-cell suspensions for the isolation of subpopulations of tumor cells. Orthotopic or heterotopic implantation of established cell lines requires 1–2 h, with 1-cm tumors arising after 2–5 weeks. Engraftment of patient tumor samples takes ∼2 h and growth of palpable tumor requires ∼14 weeks. Once established, direct xenograft tumors require 2 and 5 h for heterotopic and orthotopic implantation, respectively, and 5–6 weeks for palpable tumor growth.
引用
收藏
页码:1670 / 1680
页数:10
相关论文
共 56 条
  • [1] Jones S(2008)Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 321 1801-1806
  • [2] Sharpless NE(2006)The mighty mouse: genetically engineered mouse models in cancer drug development Nat. Rev. Drug Discov. 5 741-754
  • [3] Depinho RA(2007)Maximizing mouse cancer models Nat. Rev. Cancer 7 645-658
  • [4] Frese KK(2006)The use of targeted mouse models for preclinical testing of novel cancer therapeutics Clin. Cancer Res. 12 5277-5287
  • [5] Tuveson DA(2003)Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice Nat. Rev. Cancer 3 952-959
  • [6] Olive KP(1992)A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens Proc. Natl. Acad. Sci. USA 89 5645-5649
  • [7] Tuveson DA(2004)Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity Pancreas 29 193-203
  • [8] Rangarajan A(2006)An Clin. Cancer Res. 12 4652-4661
  • [9] Weinberg RA(2009) platform for translational drug development in pancreatic cancer Clin. Pharmacol. Ther. 85 217-221
  • [10] Fu X(1966)Direct Genet. Res. 8 295-309